Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma

Size: px
Start display at page:

Download "Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma"

Transcription

1 Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Anthony Bench Haematopathology and Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge UK

2 Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Hongxiang Liu Prof. Ming Q. Du Baljinder Matharu Bridget Manasse Dr George Follows

3 High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH)

4 Frequency of BL and HGBL-DH/TH HGBL-DH constitute around 5% of all DLBCL At least 250 predicted cases HGBL-DH per year in the UK Annual rate per 100,000 Median age at diagnosis Expected UK cases per year 5-Year Relative Survival (%) Non-Hodgkin lymphoma Marginal zone lymphoma Follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Burkitt lymphoma T-cell lymphoma Hodgkin lymphoma

5 FISH panel to aid diagnosis of Burkitt s lymphoma and DLBCL To confirm a diagnosis of BL MYC break apart probe MYC-IGH fusion probe IGK break apart probe IGL break apart probe For differential diagnosis of BL and High grade B cell lymphoma MYC break apart probe MYC-IGH fusion probe BCL2 break apart probe BCL6 break apart probe

6 High grade B cell lymphoma FISH panel 582 high grade B-cell NHL cases tested since 2008 successfully analysed, -> 97%. 564 cases No cases MYC-R MYC- IGH MYC- Amp BCL2-R BCL6-R MYC-R BCL2-R MYC-R BCL6-R MYC-R BCL2-R BCL6-R CNV at any locus BL DLBCL HGBL

7 Burkitt s lymphoma with MYC-IGH t(8;14) rearrangement Normal cells t(8;14)(q24:q32) MYC-IGH dual colour dual fusion MYC dual colour

8 Burkitt s lymphoma with MYC-IGL t(8;22) rearrangement Normal cells t(8;14)(q24:q32) MYC-IGH triple colour dual fusion MYC dual colour

9 Burkitt s lymphoma with MYC-IGL t(8;22) rearrangement MYC-IGH triple colour dual fusion MYC dual colour IGK dual colour IGL dual colour

10 Burkitt s lymphoma FISH panel? Burkitt s lymphoma MYC break apart MYC-IGH fusion MYC break apart : POSITIVE MYC-IGH fusion : POSITIVE MYC break apart : NEGATIVE MYC-IGH fusion : NEGATIVE MYC break apart : POSITIVE MYC-IGH fusion : NEGATIVE IGK or IGL : POSITIVE Review diagnosis Consider : Unusual MYC breakpoint Burkitt-like lymphoma with 11q aberration

11 High grade B cell lymphoma FISH panel 582 high grade B-cell NHL cases tested since 2008 successfully analysed, -> 97%. 564 cases No cases MYC-R MYC- IGH MYC- Amp BCL2-R BCL6-R MYC-R BCL2-R MYC-R BCL6-R MYC-R BCL2-R BCL6-R CNV at any locus BL DLBCL HGBL

12 High grade B cell lymphoma with MYC rearrangement MYC dual colour MYC-IGH dual colour dual fusion MYC-IGH rearrangement observed

13 High grade B cell lymphoma with MYC rearrangement MYC dual colour MYC-IGH dual colour dual fusion MYC-IGH rearrangement with MYC breakpoint 5 of MYC probes

14 High grade B cell lymphoma with MYC rearrangement MYC dual colour MYC-IGH dual colour dual fusion MYC-IGH rearrangement with MYC breakpoint within 5 MYC probe

15 High grade B cell lymphoma FISH panel 582 high grade B-cell NHL cases tested since 2008 successfully analysed, -> 97%. 564 cases No cases MYC-R MYC- IGH MYC- Amp BCL2-R BCL6-R MYC-R BCL2-R MYC-R BCL6-R MYC-R BCL2-R BCL6-R CNV at any locus BL DLBCL HGBL

16 High grade B cell lymphoma with MYC and BCL2 rearrangement 83/female, LN CD20+, CD10+, BCL6+, BCL2+, Ki67~90% MYC dual colour BCL2 dual colour BCL2-IGH dual colour dual fusion

17 High grade B cell lymphoma with MYC and BCL2 and BCL6 rearrangement 48/male, LN CD20+, CD10+, CD79a+, BCL6+, BCL2+, Ki67~90% MYC dual colour BCL2 dual colour BCL6 dual colour

18 High grade B cell lymphoma FISH panel 582 high grade B-cell NHL cases tested since 2008 successfully analysed, -> 97%. 564 cases No cases MYC-R MYC- IGH MYC- Amp BCL2-R BCL6-R MYC-R BCL2-R MYC-R BCL6-R MYC-R BCL2-R BCL6-R CNV at any locus BL DLBCL HGBL

19 HGBL / DLBCL FISH panel? Burkitt s lymphoma / HGBL / DLBCL MYC : POSITIVE MYC-IGH : POSITIVE BCL2 : NEGATIVE BCL6 : NEGATIVE No significant CNV MYC break apart MYC-IGH fusion BCL2 break apart BCL6 MYC : POSITIVE BCL2 or BCL6: POSITIVE May have CNV MYC : NEGATIVE May have CNV Favours Burkitt s lymphoma Favours HGBL with MYC and BCL2 and/or BCL6 Favours HGBL, NOS or DLBCL, NOS IMPORTANT : Integrate with morphogical and IHC information e.g. Ki67

20 Burkitt s lymphoma MYC and high grade B cell lymphoma MYC translocations are usually the sole chromosomal aberration or are associated with few additional alterations MYC translocations involve IGH or IGK or IGL High grade B cell lymphoma MYC translocation may be single hit or double hit MYC translocations may involve partners other than IG loci. Frequently associated with complex cytogenetic karyotype. Generally felt to be associated with a less favourable outcome compared to MYC-negative cases

21 Prognostic relevance of MYC, BCL2 and BCL6 rearrangements in high grade B cell lymphoma Presence of MYC rearrangement associated with less favourable outcome in DLBCL

22 Prognostic relevance of MYC, BCL2 and BCL6 rearrangements in high grade B cell lymphoma HGBL with MYC and BCL2 may represent a less favourable group compared to HGBL with MYC and BCL6 Ye et al 2016

23 MYC+, non-ig DH+, non-ig DH- MYC- MYC+, IG DH+, IG

24 High grade B cell lymphoma with MYC and BCL2 or BCL6 HGBL with MYC and BCL2 or BCL6 double hit generally felt to perform less well on standard chemotherapy R-CHOP But : MYC + BCL2 + : Unfavourable MYC + BCL6 + : No difference MYC-IG : MYC-non-IG : Unfavourable No difference May explain why some studies do not find a less favourable outcome for double hit lymphoma More intensive chemotherapy regimes (e.g. DA-EPOCH-R) give better response to induction and improves progression free survival BUT overall survival is not improved

HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD

HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD OUTLINE High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Patient presentation 2008/2016

More information

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Treseler, MD, PhD University of California San Francisco

More information

The next lymphoma classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno

The next lymphoma classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Evolution of classification The next classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno The Lymphoma Forum of Excellence, Bellinzona, January 2011 Rappaport Lukes and Collins (immunophenotype)

More information

Defined lymphoma entities in the current WHO classification

Defined lymphoma entities in the current WHO classification Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes

More information

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid

More information

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and

More information

Recent advances in the genetics & biology of lymphoma

Recent advances in the genetics & biology of lymphoma Recent advances in the genetics & biology of lymphoma Chris Bacon Northern Institute for Cancer Research Newcastle University & Newcastle Upon Tyne Hospitals NHS Foundation Trust Lymphoma Rate per 100,000

More information

High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,

High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li, High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li, M.D., Ph.D. Fudan University Shanghai Cancer Center

More information

Aggressive B-cell Lymphomas

Aggressive B-cell Lymphomas Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO

More information

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help

More information

High-Grade B-cell Lymphoma Double Hit or Double Expressing

High-Grade B-cell Lymphoma Double Hit or Double Expressing High-Grade B-cell Lymphoma Double Hit or Double Expressing Professeur Alexandra Traverse-Glehen Hematopathology Hospices Civils de Lyon Université Lyon 1 France MYC-R confer inferior pronostic DOUBLE/TRIPLE

More information

Comparison of FISH, CpG-stimulation, chromosomal microarray and mate pair sequencing in 20 patients with CLL or lymphoma

Comparison of FISH, CpG-stimulation, chromosomal microarray and mate pair sequencing in 20 patients with CLL or lymphoma Comparison of FISH, CpG-stimulation, chromosomal microarray and mate pair sequencing in 20 patients with CLL or lymphoma Stephanie Smoley Cancer Genomics Consortium August 9 th, 2017 2016 MFMER slide-1

More information

Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?

Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology 2012, 61, 1214 1218. DOI: 10.1111/j.1365-2559.2012.04351.x SHORT REPORT Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?

More information

Aggressive B cell Lymphomas

Aggressive B cell Lymphomas Aggressive B cell Lymphomas I have nothing to disclose. Disclosures Raju K. Pillai City of Hope National Medical Center Outline WHO 2016 Classification Large B cell Lymphomas New entities and changes in

More information

Pathology of aggressive lymphomas

Pathology of aggressive lymphomas Institute of Pathology Pathology of aggressive lymphomas Leticia Quintanilla-Martinez Changes in the new 2016 WHO Aggressive B-cell lymphoid neoplasms Major changes that impact how cases should be evaludated

More information

ESMO DOUBLE-HIT LYMPHOMAS

ESMO DOUBLE-HIT LYMPHOMAS ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in

More information

Management of high-risk diffuse large B cell lymphoma: case presentation

Management of high-risk diffuse large B cell lymphoma: case presentation Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January

More information

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic

More information

The development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory

The development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell

More information

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival in partnership with MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival Brian A Walker Centre for Myeloma Research,

More information

Aggressive B-Cell Lymphomas

Aggressive B-Cell Lymphomas Aggressive B-cell Lymphomas Aggressive B-Cell Lymphomas Stephen Hamilton Dutoit Institute of Pathology Aarhus Kommunehospital B-lymphoblastic lymphoma Diffuse large cell lymphoma, NOS T-cell / histiocyte-rich;

More information

Pathology of aggressive lymphomas

Pathology of aggressive lymphomas Institute of Pathology Pathology of aggressive lymphomas Leticia Quintanilla-Martinez Changes in the new 2016 WHO Aggressive B-cell lymphoid neoplasms Major changes that impact how cases should be evaludated

More information

LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES.

LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES. Congreso Nacional SEAP 2013. LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES. Santiago Montes Moreno Servicio de Anatomía Patológica, HUMV

More information

Aggressive B cell Lymphomas

Aggressive B cell Lymphomas Aggressive B cell Lymphomas Raju K. Pillai City of Hope National Medical Center I have no disclosures Outline What is new in the WHO 2016 classification Insights from genomic studies Double Hit Lymphoma

More information

Methods used to diagnose lymphomas

Methods used to diagnose lymphomas Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry

More information

Citation International Journal of Hematology, 2013, v. 98 n. 4, p The original publication is available at

Citation International Journal of Hematology, 2013, v. 98 n. 4, p The original publication is available at Title Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma Author(s) So, JCC; Yung, KH; Chu, ML; Wan,

More information

Prevalent lymphomas in Africa

Prevalent lymphomas in Africa Prevalent lymphomas in Africa Dr Zainab Mohamed Clinical Oncologist GSH/UCT Groote Schuur Hospital Disclaimer I declare that I have no conflict of interest Groote Schuur Hospital Denis Burkitt 1911-1993

More information

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of

More information

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22) PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green

More information

Lymphoma Update: Lymphoma Update: What s Likely to be New in the New WHO. Patrick Treseler, MD, PhD University of California San Francisco

Lymphoma Update: Lymphoma Update: What s Likely to be New in the New WHO. Patrick Treseler, MD, PhD University of California San Francisco Lymphoma Update: What s Likely to be New in the New WHO Blood 127:2375; 2016 Patrick Treseler, MD, PhD University of California San Francisco Lymphoma Update: What IS New in the New WHO! Patrick Treseler,

More information

Aggressive B-cell Lymphoma 2013

Aggressive B-cell Lymphoma 2013 Aggressive B-cell Lymphoma 2013 Diffuse Large B-Cell Lymphoma Burkitt Lymphoblastic lymphoma Gray zone Intermediate DLBCL/HL Intermediate BL/DLBCL Diffuse Large B-cell lymphoma Common morphology: diffuse

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

Diagnostic Molecular Pathology of Lymphoid Neoplasms

Diagnostic Molecular Pathology of Lymphoid Neoplasms Diagnostic Molecular Pathology of Lymphoid Neoplasms (Part II) Rational use of molecular testing in lymphomas Beirut, Lebanon Friday December 2, 2011: Hematopathology Session Adam Bagg University of Pennsylvania

More information

LYMPHOMAS an overview of some subtypes of NHLs

LYMPHOMAS an overview of some subtypes of NHLs One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid

More information

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy?

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION

More information

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma 160 Original Article Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma Hong-wei Zhang 1,#, Niu-liang Cheng 1*, Zhen-wen Chen 2, Jin-fen Wang 3, Su-hong Li 3, Wei Bai 3 1 Department of Biochemistry

More information

Double hit lymphoma Clinical perspectives

Double hit lymphoma Clinical perspectives Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression

More information

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin

More information

IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas

IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas Hematological Oncology Hematol Oncol 2015; 33: 50 55 Published online in Wiley Online Library (wileyonlinelibrary.com).2217 Supplement Article IX. Is it only about MYC? How to approach the diagnosis of

More information

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas NAIVE -B LYMPHOCYTE MEMORY CELL CLL MCL FL MZL Small cell size Low proliferation

More information

Initial Diagnosis and Treatment 81 Male

Initial Diagnosis and Treatment 81 Male Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,

More information

EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH

EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH CASE E1 M: 68 yrs Left destructive sinonasal lesion.?lymphoma?adenocarcinoma CD20 CD10 BCL6 MIB1 Answers Diffuse large B cell

More information

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative

More information

Small B-cell (Histologically Low Grade) Lymphoma

Small B-cell (Histologically Low Grade) Lymphoma Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma

More information

Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing

Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics

More information

5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful

5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful www.ascp.org/ascp2014 5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful Kathryn Rizzo, DO, PhD VIRGINIA COMMONWEALTH UNIVERSITY Department of Pathology School of Medicine

More information

Update on the Classification of Aggressive B-cell Lymphomas and Hodgkin Lymphoma

Update on the Classification of Aggressive B-cell Lymphomas and Hodgkin Lymphoma Update on the Classification of Aggressive B-cell Lymphomas and Hodgkin Lymphoma Nancy Lee Harris, M. D. Massachusetts General Hospital Harvard Medical School Aggressive B-cell Lymphomas WHO 4 th Edition

More information

Follicular Lymphoma: the WHO

Follicular Lymphoma: the WHO Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure

More information

WHO UPDATE ON LYMPHOMAS. Dr Priya Mary Jacob Asst Professor, Pathology.

WHO UPDATE ON LYMPHOMAS. Dr Priya Mary Jacob Asst Professor, Pathology. WHO UPDATE ON LYMPHOMAS Dr Priya Mary Jacob Asst Professor, Pathology 3 rd 4 th 4 th revised 2001 2008 2017 The Change The Significance of the Change- Diagnostic, Prognostic The Rationale behind the change.

More information

Abstract. Hematopathology / HIGH KI-67 INDEX AND STARRY-SKY PATTERN IN BL AND DLBCL

Abstract. Hematopathology / HIGH KI-67 INDEX AND STARRY-SKY PATTERN IN BL AND DLBCL Hematopathology / HIGH KI-67 INDEX AND STARRY-SKY PATTERN IN BL AND DLBCL Histopathology and Immunohistochemistry in Distinguishing Burkitt Lymphoma From Diffuse Large B-Cell Lymphoma With Very High Proliferation

More information

Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination

Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination AJCP / Case Report Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination A Cytogenetic Finding of Potential Prognostic Value Shivakumar Subramaniyam, PhD, Cynthia M.

More information

DOUBLE-HIT AND TRIPLE-HIT LYMPHOMAS: NEW PERSPECTIVES FOR THEIR CLASSIFICATION

DOUBLE-HIT AND TRIPLE-HIT LYMPHOMAS: NEW PERSPECTIVES FOR THEIR CLASSIFICATION DOUBLE-HIT AND TRIPLE-HIT LYMPHOMAS: NEW PERSPECTIVES FOR THEIR CLASSIFICATION *Cristiano Claudino Oliveira, Maria Aparecida Custódio Domingues Department of Pathology, Botucatu School of Medicine, São

More information

XCyting DNA FISH Probes

XCyting DNA FISH Probes XCyting DNA FISH Catalog 2017/18 MetaSystems 1. Industriestr. 7 D-68804 Altlussheim Germany Phone: +49 6205 2927610 Fax: +49 6205 2927629 E-Mail info: info@metasystems-probes.com E-Mail orders: orders@metasystems-probes.com

More information

Kim et al. Journal of Hematology & Oncology 2013, 6:76

Kim et al. Journal of Hematology & Oncology 2013, 6:76 Kim et al. Journal of Hematology & Oncology 2, 6:76 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Significance of MYC/BCL2 Double Expression in Diffuse Large B-cell Lymphomas: A Single-center Observational Preliminary Study of 88 Cases

Significance of MYC/BCL2 Double Expression in Diffuse Large B-cell Lymphomas: A Single-center Observational Preliminary Study of 88 Cases Original Article Significance of MYC/BCL Double Expression in Diffuse Large B-cell Lymphomas: A Single-center Observational Preliminary Study of 88 Cases Chutima Pinnark 1 ; Jerasit Surintrspanont ; Thiamjit

More information

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives

More information

The 11th International Course on the Pathology of the Digestive System CASE 2. Alina Nicolae MD, PhD

The 11th International Course on the Pathology of the Digestive System CASE 2. Alina Nicolae MD, PhD The 11th International Course on the Pathology of the Digestive System CASE 2 Alina Nicolae MD, PhD Clinical History 20-year-old female patient Jan 2016 - acute right lower quadrant abdominal pain, nausea,

More information

Approach to Core Biopsy Specimens

Approach to Core Biopsy Specimens BDIAP 108th Symposium on Haematopathology Joint Meeting of the BDIAP and BLPG at-bristol, Anchor Road, Harbourside, Bristol BS1 5DB 15th - 17th May 2014 Approach to Core Biopsy Specimens Dr Stefan Dojcinov

More information

QUANT BCL2/IGH Cat Real Time Quantitative PCR of t(14;18) (Bcl2/IgH) for diagnosis and monitoring of follicular Cell lymphoma

QUANT BCL2/IGH Cat Real Time Quantitative PCR of t(14;18) (Bcl2/IgH) for diagnosis and monitoring of follicular Cell lymphoma QUANT BCL2/IGH Cat.1.006 Real Time Quantitative PCR of t(14;18) (Bcl2/IgH) for diagnosis and monitoring of follicular Cell lymphoma Follicular)Cell)Lymphoma)(FCL))is)the)most)common)indolent)non7Hodgkin

More information

Case year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease

Case year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease Codirectors Tsieh Sun, M.D., FASCP Francisco Vega, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Houston Texas There is no conflict of interest involved in the content and presentation

More information

Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU

Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-hodgkin B-cell lymphoma

Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-hodgkin B-cell lymphoma NEOPLASIA Brief report Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-hodgkin B-cell lymphoma Fabrice Jardin, Christian Bastard, Nathalie Contentin,

More information

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphoma: The Basics. Dr. Douglas Stewart Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What

More information

B Cell Lymphoma: Aggressive

B Cell Lymphoma: Aggressive B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant

More information

Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression

Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome

More information

KREATECH DIAGNOSTICS SOLID TUMORS

KREATECH DIAGNOSTICS SOLID TUMORS KREATECH DIAGNOSTICS SOLID TUMORS RF POSEIDON SOLUTIONS FOR SOLID TUMOR FISH DIAGNOSTICS TABLE OF CONTENTS Breast Cancer 3 Bladder Cancer 4 Cervical Cancer 4 Lung Cancer 5 Prostate Cancer 6 Thyroid Carcinoma

More information

A Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D.

A Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D. A Practical Guide To Diagnose B-Cell Lymphomas on FNAs Nancy P. Caraway, M.D. Major Factors Impacting Dx Lymphomas on Small Bxs Classification systems Immunophenotyping by multiprobe flow cytometry and

More information

September 04, 2008

September 04, 2008 27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates September 04, 2008 Dear Valued Client: As you may be aware, in recent years there has been a tremendous challenge in

More information

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship

More information

Molecular Diagnostics in the Workup of Lymphomas for the General Pathologist. Outline. Role of Molecular Testing in Lymphoma Diagnosis

Molecular Diagnostics in the Workup of Lymphomas for the General Pathologist. Outline. Role of Molecular Testing in Lymphoma Diagnosis Molecular Diagnostics in the Workup of Lymphomas for the General Pathologist L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Outline Gene rearrangement studies / Clonality Translocations / mutations

More information

Activation of cellular proto-oncogenes to oncogenes. How was active Ras identified?

Activation of cellular proto-oncogenes to oncogenes. How was active Ras identified? Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,

More information

Double Hit Lymphoma 3/2016

Double Hit Lymphoma 3/2016 Double Hit Lymphoma 3/2016 Thomas M. Habermann et al. JCO 2006;24:3121-3127 View from the Rear View Mirror: FFS and OS after CHOP vs RCHOP MYC-expressing lymphomas Burkitt Lymphoma Positive by definition

More information

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide

More information

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma AJCP /CASE REPORT CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma Yuan Miao, MD, 1,2 Pei Lin, MD, 1 Wei Wang, MD, 1 L. Jeffrey Medeiros, MD,

More information

Highlights of ICML 2015

Highlights of ICML 2015 Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465

More information

3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!

3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Judith A. Ferry Massachusetts General Hospital Disclosure of Relevant Financial Relationships USCAP requires that all

More information

Oncology Cytogenetics Diagnostic Service - User Guide 2014

Oncology Cytogenetics Diagnostic Service - User Guide 2014 Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188

More information

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential

More information

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013 Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie

More information

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS

More information

WHO 2016 update lymphoid neoplasms. Dr Sue Morgan Alfred Hospital, Melbourne

WHO 2016 update lymphoid neoplasms. Dr Sue Morgan Alfred Hospital, Melbourne WHO 2016 update lymphoid neoplasms Dr Sue Morgan Alfred Hospital, Melbourne WHO 4 th edition 2008 Established guideline worldwide for diagnosis of haematological malignancy for the last 9 years Significant

More information

9/28/2017. Follicular Lymphoma and Nodal Marginal Zone Lymphoma. Follicular Lymphoma Definition. Low-Grade B-Cell Lymphomas in WHO Classification

9/28/2017. Follicular Lymphoma and Nodal Marginal Zone Lymphoma. Follicular Lymphoma Definition. Low-Grade B-Cell Lymphomas in WHO Classification and L. Jeffrey Medeiros, MD DISCLOSURES I do not have anything to disclose Low-Grade B-Cell Lymphomas in WHO Classification Lymphoma Type Frequency Follicular lymphoma 22.1 % Extranodal MALT-lymphoma 7.6

More information

Molecular Diagnosis. Nucleic acid based testing in Oncology

Molecular Diagnosis. Nucleic acid based testing in Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,

More information

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour 7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic

More information

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine

More information

Approach at lymph node pathology and ancillary techniques

Approach at lymph node pathology and ancillary techniques Approach at lymph node pathology and ancillary techniques Hans Konrad Müller-Hermelink Institute of Pathology, University of Würzburg Würzburg, Germany 1000 km 400 km Würzburg Germany: 80.000.000 population

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

Haematology Probes for Multiple Myeloma

Haematology Probes for Multiple Myeloma Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex

More information

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor

More information

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case

Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Int J Clin Exp Pathol 2014;7(10):7100-7104 www.ijcep.com /ISSN:1936-2625/IJCEP0001717 Case Report Parotid gland follicular lymphoma lacking both cytoplasmic and surface light chains: a rare case Jenny

More information

Molecular Pathogenesis of Multiple Myeloma:

Molecular Pathogenesis of Multiple Myeloma: Molecular Pathogenesis of Multiple Myeloma: Ig translocations hyperdiploid vs non-hyperdiploid CYCLIN D dysregulation other oncogenic events Michael Kuehl MM: post-germinal center tumor of long-lived BM

More information

NEW ENTITIES IN AGGRESSIVE B CELL LYMPHOMA. Joon Seong Park, M.D. Dept. of Hematology-Oncology Ajou University School of Medicine

NEW ENTITIES IN AGGRESSIVE B CELL LYMPHOMA. Joon Seong Park, M.D. Dept. of Hematology-Oncology Ajou University School of Medicine NEW ENTITIES IN AGGRESSIVE B CELL LYMPHOMA Joon Seong Park, M.D. Dept. of Hematology-Oncology Ajou University School of Medicine Historical background of Lymphoma classification Rappaport classification

More information

Hematopathology Service Memorial Sloan Kettering Cancer Center, New York

Hematopathology Service Memorial Sloan Kettering Cancer Center, New York SH2017-0334 t(14;18) Negative Follicular Lymphoma with 1p36 abnormality associated with In Situ Follicular Neoplasia with t(14;18) translocation Pallavi Khattar MD, Jennifer Maerki MD, Alexander Chan MD,

More information

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Outline Transplant Congenital Autoimmunity T-cell/immune

More information

Ferrata Storti Foundation

Ferrata Storti Foundation Articles Introduction Non-Hodgkin Lymphomas Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma Sietse M. Aukema, 1,2,3 Markus

More information